ANA-12 Targets and Inhibits BDNF/TrkB Signaling to Alleviate Pain Behaviors in Rheumatoid Arthritis Mice
Neurochemical Research · 2025
DOI: 10.1007/s11064-025-04487-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurochemical Research, 2025. Verfasst von Man Yuan und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, School of Basic Medical Sciences, Hubei University of Science and Technology, Xianning, China. Hauptthemen laut MEDLINE: Brain-Derived Neurotrophic Factor, Receptor, trkB, Arthritis, Rheumatoid, Pain. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Joint supported by Hubei Provincial Natural Science Foundation and Xianning-of China.
Abstract (Originalsprache)
Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease. Sensitization of central pain pathways by pro-inflammatory mediators has been implicated in RA pain. Locus coeruleus (LC) functions in pain pathways. Brain-derived neurotrophic factor (BDNF) participates in the modulation of nociception and pain. A mouse model of RA immunized with collagen-induced arthritis (CIA) was used for investigating the mechanisms of pain relief by administration of the tropomyosin receptor kinase B (TrkB) receptor antagonist ANA-12. We measured the pain behaviors and locomotor activity and found increased pain sensitivity and locomotor deficit in RA mice; ANA-12 treatment reduced pain behaviors and promoted locomotor function recovery. The glial activation and increased activities of BDNF/TrkB and MAPK signal pathways were found in LC of RA mice. The components of NLRP3 inflammasome were all increased and consequently enhanced the production of pro-inflammatory cytokine interleukin (IL)-1β. Upon ANA-12 treatment, glial cell activation was reduced, BDNF/TrkB and MAPK pathways were suppressed, and the expression levels of the above-mentioned proteins were reduced. Finally, U251 cells were conducted to further confirm the regulatory mechanisms of ANA-12 on inflammation. The results showed the colocalization of BDNF/NLRP3/IL-1β and GFAP. ANA-12 treatment decreased the protein levels of BDNF, TrkB, MAPK, NLRP3, and caspase-1 in IL-1β-induced cells. Besides, ANA-12 treatment decreased NLRC4 and AIM2 inflammasomes both in RA mice and IL-1β-induced cells. These results suggested that ANA-12 alleviates hyperalgesia in RA mice by inhibiting BDNF/TrkB signaling in LC, thereby reducing glial cell activation and inflammatory cytokine release.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, School of Basic Medical Sciences, Hubei University of Science and Technology, Xianning, China.
- School of Pharmacy, School of Basic Medical Sciences, Hubei University of Science and Technology, Xianning, China. xiemin2020a@163.com.
Förderung
- Joint supported by Hubei Provincial Natural Science Foundation and Xianning-of China
Zitieren
APA
Yuan, M., Zhang, L., Zheng, Y., & Xie, M. (2025). ANA-12 Targets and Inhibits BDNF/TrkB Signaling to Alleviate Pain Behaviors in Rheumatoid Arthritis Mice. Neurochemical Research. https://doi.org/10.1007/s11064-025-04487-8
Vancouver
Yuan M, Zhang L, Zheng Y, Xie M. ANA-12 Targets and Inhibits BDNF/TrkB Signaling to Alleviate Pain Behaviors in Rheumatoid Arthritis Mice. Neurochemical Research. 2025. doi:10.1007/s11064-025-04487-8
BibTeX
@article{Yuan2025,
author = {Yuan, Man and Zhang, Long and Zheng, Ye and Xie, Min},
title = {ANA-12 Targets and Inhibits BDNF/TrkB Signaling to Alleviate Pain Behaviors in Rheumatoid Arthritis Mice},
journal = {Neurochemical Research},
year = {2025},
doi = {10.1007/s11064-025-04487-8}
}
EUVIMED